The trial compared the pharmacokinetic (PK) profile of L-Dopa (levodopa) produced by a single oral dose of a prototype, sustained-release tablet of XP21279 to that of a near-equivalent single dose of oral L-Dopa. The trial demonstrated that XP21279 produced a more sustained exposure of L-Dopa compared to oral L-Dopa dosed in the same healthy subjects. XP21279 was well-tolerated in this first trial in humans.
Ronald Barrett, XenoPort’s CEO, said: “We believe that this clinical trial serves as a solid proof of concept for XP21279. We believe that an optimized formulation of XP21279 could provide therapeutic benefits to patients with Parkinson’s disease, particularly in avoiding periods of wearing-off or the return of symptoms that occur during the day with oral L-Dopa therapy.”